Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

72.26 -0.79 (-1.08%)
Streaming Delayed Price Updated: 10:35 AM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 Next >
News headline image
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout. 
Via Chartmill
News headline image
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗
Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock ↗
One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds. 
Via The Motley Fool
News headline image
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge ↗
This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline. 
Via The Motley Fool
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Preview: Mirum Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Mirum Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup ↗
Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities. 
Via Chartmill
News headline image
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup ↗
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout. 
Via Chartmill
News headline image
This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Mirum Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Expectations For Mirum Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews ↗
 
Via Benzinga
News headline image
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential ↗
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch. 
Via Chartmill
News headline image
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template ↗
MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors. 
Via Chartmill
News headline image
Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance ↗
Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum ↗
Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching. 
Via Chartmill
News headline image
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish ↗
Livmarli tablets will be available in June through Mirum Access Plus pharmacy. 
Via Stocktwits
News headline image
FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol ↗
Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million. 
Via Benzinga
News headline image
We Tested Top Stocks; Here’s What’s Best For Your Money ↗
Discover the top-performing stocks with our analysis. In this video, we dive into the Bollinger Band Squeeze strategy while scanning for opportunities. 
Via Talk Markets
News headline image
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024 ↗
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.